Flu vaccine coverage drops in Australia, experts call for urgent action
Australian health experts are sounding the alarm over low flu vaccination rates as winter sets in, warning children and older adults are particularly vulnerable to a dangerous and potentially deadly flu season.
Despite being eligible for free flu shots, fewer than one in three children under five, and just 32.5 per cent of Australians aged 65 and over, have been vaccinated so far this year.
In the first three months of this year, 84 people died from Influenza, according to data from the Australian Bureau of Statistics, released last week.
A social scientist with the University of Sydney's Infectious Diseases Institute, Professor Julie Leask, said the nation's flu vaccination coverage is 'perpetually low'.
'Our influenza vaccination rates in Australia are dire and they're not improving,' she said
Professor Leask said some flu-related hospitalisations and deaths were 'potentially preventable'.
'The vaccine isn't perfect, but it's much better than zero, which is what you're looking at if you don't have a vaccine. Of course, there are other measures to reduce the risk of respiratory infections, but nothing matches an effectiveness of even between 50 and 70 per cent and even better in children having that vaccine,' she said.
The National Centre for Immunisation Research found that just 62 per cent of people received a flu vaccine by the end of the 2024 season, a drop compared to 2022.
Children, aged six month to five year olds, had a low coverage rate of 28 per cent.
Professor Leask said new data from the 2025 National Vaccination Insights Project, which surveyed more than 2000 adults in March, shows many Australians are underestimating the seriousness of influenza, with nearly one-third not having had a flu shot in the past two years.
By March, only 32.5 per cent of people aged 65 and over, one of the most vulnerable groups, had received their flu shot, a rate that shows no improvement on previous years.
32 per cent of all adults surveyed reported they hadn't received a flu vaccine at all in the past two years.
Cost, inconvenience, and access, especially in rural areas, were key barriers to getting vaccinated, according to the survey.
The most common places people received their flu shot were GP clinics, pharmacies, and workplaces. Although many respondents said they planned to get vaccinated, concern about catching the flu remained low, even among groups at higher risk of severe illness.
While the majority of respondents believed the flu vaccine was safe, 22 per cent did not.
Professor Leask suggested that the COVID-19 pandemic may have contributed to the unusually low vaccination rates.
'The idea here is that after Covid, people were really over the topic of vaccination,' she said.
'There might have been a bit of a backlash in some groups about that, and people wanted to get on with their lives and were a little bit disengaged from vaccination.'
Dr Paul Griffin, an infectious diseases physician, underscored the yearly devastation caused by the flu.
'We know that there's deaths in the order of thousands, hospitalisations around 20,000 every year,' Dr Griffin said.
'Hundreds of thousands of doctors at visits and quite a lot of financial implications in terms of lost work days. So while a lot of people underestimate the flu at the moment, the impact is very significant.'
He said people at higher risk include children, older adults, pregnant women, people with chronic medical conditions, Aboriginal and Torres Strait Islanders, and smokers.
'It's not just a flu, it's a very severe viral infection in its own right and can be life threatening,' he said.
Professor Leask said that dispelling myths, along with effective campaigning and communication, and convenient access could help increase vaccine uptake.
'We need to keep busting those myths, such as the flu vaccine gives you the flu, it doesn't.
'Campaigns need to remind people of the benefits to self and others if we get a vaccine. We might not think we're at risk, but we may help protect other people who are.
'We might not think we're at risk, but we may help protect other people who are,' she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sydney Morning Herald
5 hours ago
- Sydney Morning Herald
A medicine shortage is heaping undue stress on schoolkids like Alon
'The school has been very supportive, and we haven't had any phone calls going 'this is ridiculous', but in terms of his marks, even just he gets a little disappointed in himself because he wants to do better and he wants to finish the math test, and he just couldn't concentrate,' she says. 'It's not because he's aiming to be annoying and waste time in class.' While many schools are understanding and work with students with ADHD, the medication shortage is creating an extra layer of stress for families with children with additional needs, according to development pediatrician Dr Suzi Riess. Riess, who treats children with behavioural issues, says the scarcity of Concerta is increasing demand for other medications and causing further shortages. She says more doctors are having to find alternatives but they must be cautious when switching medications. 'You have to be able to start low [with dosage] and go up slowly, and for families it's very stressful to navigate that,' Riess explains. 'I've had families who have finally found a good combination of medication, and it's been really hard for them because they've experienced the benefit.' For those living regionally or in outer suburbs, that can mean driving to multiple pharmacies to find the medication they need. It's also important for schools to be able to respond to changes in the behaviour of children, according to University of Melbourne associate professor of education Matthew Harrison. Harrison, who specialises in inclusive education, helps train teachers on how to work with neurodivergent kids and also has ADHD himself. 'For teachers who are trying to plan supports for young people, if someone's needs are changing based on whether they're medicated or not, it can be really stressful,' Harrison says. 'It's difficult for teachers, it's difficult for the parents, and of course, it's most difficult for the young people themselves.' He says for many neurodivergent students, medication also helps them socially – not just in the classroom. It can also allow them to be more engaged and present. Harrison says it is important that schools foster calm, predictable environments. 'It's having routines and systems in place, even things about what happens when we arrive at school, what happens when we enter the classroom,' he suggests. Loading Fostering positive relationships between teachers and their students is key, so when young people are struggling they can be open about it, he says. '[Neurodivergent] kids have to feel safe and happy first before they're learning.' Sydney-based mum and accredited ADHD coach Sharon Collon agrees, and says she has seen a surge in parents raising concerns about limited medication supply. 'We're having increase of more challenging behaviours at home and school environment,' she says. 'We are seeing increased levels of distress.' Collon says her husband and three sons all have ADHD, and finding the 'holy grail' of medication meant going through a lot of trial and error. 'Everyone is unique, and some medications can make their behaviour worse or have negative side effects, so when you finally find the one that works for your child … to then have to stop it or swap it for another because of a shortage, it causes so much stress for families.' One of her sons, whose ADHD had been well managed, had to switch from a medicine that was scarce. 'He got suspended twice in one week.' She says it was also a blow to his self-esteem: he wanted to do well and had never faced disciplinary action at school. 'And it was all because he hadn't had the right medication at that time.' Collon says teachers supporting students with neurodiversity were struggling with medication disruptions but she urged them to opt for 'connection'. 'You can't discipline ADHD out of a child, and anytime someone tries to do that all it does is cause shame,' she says. Kids may need to move more or go for 'brain breaks' where they go for a short walk. They may also need additional supports like visual cues. Many schools and teachers are already doing what they can, she explains, but it's important for them to communicate with parents about what's going on. Mum Nadine Barkay is already concerned about what happens next for Alon. 'My community chemist has run out of Ritalin ... and they don't have a due date for it,' she says. They eventually found it at another pharmacy, but the shortage is prompting the family to consider what to do next. The Department of Education was asked if it was aware of the shortages. 'Schools ensure that every student is able to attend and learn in a safe environment, regardless of a student's medical condition,' a spokesperson said in a statement.
The Age
5 hours ago
- The Age
A medicine shortage is heaping undue stress on schoolkids like Alon
'The school has been very supportive, and we haven't had any phone calls going 'this is ridiculous', but in terms of his marks, even just he gets a little disappointed in himself because he wants to do better and he wants to finish the math test, and he just couldn't concentrate,' she says. 'It's not because he's aiming to be annoying and waste time in class.' While many schools are understanding and work with students with ADHD, the medication shortage is creating an extra layer of stress for families with children with additional needs, according to development pediatrician Dr Suzi Riess. Riess, who treats children with behavioural issues, says the scarcity of Concerta is increasing demand for other medications and causing further shortages. She says more doctors are having to find alternatives but they must be cautious when switching medications. 'You have to be able to start low [with dosage] and go up slowly, and for families it's very stressful to navigate that,' Riess explains. 'I've had families who have finally found a good combination of medication, and it's been really hard for them because they've experienced the benefit.' For those living regionally or in outer suburbs, that can mean driving to multiple pharmacies to find the medication they need. It's also important for schools to be able to respond to changes in the behaviour of children, according to University of Melbourne associate professor of education Matthew Harrison. Harrison, who specialises in inclusive education, helps train teachers on how to work with neurodivergent kids and also has ADHD himself. 'For teachers who are trying to plan supports for young people, if someone's needs are changing based on whether they're medicated or not, it can be really stressful,' Harrison says. 'It's difficult for teachers, it's difficult for the parents, and of course, it's most difficult for the young people themselves.' He says for many neurodivergent students, medication also helps them socially – not just in the classroom. It can also allow them to be more engaged and present. Harrison says it is important that schools foster calm, predictable environments. 'It's having routines and systems in place, even things about what happens when we arrive at school, what happens when we enter the classroom,' he suggests. Loading Fostering positive relationships between teachers and their students is key, so when young people are struggling they can be open about it, he says. '[Neurodivergent] kids have to feel safe and happy first before they're learning.' Sydney-based mum and accredited ADHD coach Sharon Collon agrees, and says she has seen a surge in parents raising concerns about limited medication supply. 'We're having increase of more challenging behaviours at home and school environment,' she says. 'We are seeing increased levels of distress.' Collon says her husband and three sons all have ADHD, and finding the 'holy grail' of medication meant going through a lot of trial and error. 'Everyone is unique, and some medications can make their behaviour worse or have negative side effects, so when you finally find the one that works for your child … to then have to stop it or swap it for another because of a shortage, it causes so much stress for families.' One of her sons, whose ADHD had been well managed, had to switch from a medicine that was scarce. 'He got suspended twice in one week.' She says it was also a blow to his self-esteem: he wanted to do well and had never faced disciplinary action at school. 'And it was all because he hadn't had the right medication at that time.' Collon says teachers supporting students with neurodiversity were struggling with medication disruptions but she urged them to opt for 'connection'. 'You can't discipline ADHD out of a child, and anytime someone tries to do that all it does is cause shame,' she says. Kids may need to move more or go for 'brain breaks' where they go for a short walk. They may also need additional supports like visual cues. Many schools and teachers are already doing what they can, she explains, but it's important for them to communicate with parents about what's going on. Mum Nadine Barkay is already concerned about what happens next for Alon. 'My community chemist has run out of Ritalin ... and they don't have a due date for it,' she says. They eventually found it at another pharmacy, but the shortage is prompting the family to consider what to do next. The Department of Education was asked if it was aware of the shortages. 'Schools ensure that every student is able to attend and learn in a safe environment, regardless of a student's medical condition,' a spokesperson said in a statement.
The Advertiser
5 hours ago
- The Advertiser
'Game changer' diabetes pill a step closer after trials
Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug. Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug. Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug. Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug.
